Oseltamivir for critically ill patients with influenza: a randomised trial
File(s) Lancet Submission_revision3_clean.docx (4.21 MB)
Accepted version
Author(s)
REMAP-CAP, Investigators
Murthy, Srinivas
Gordon, Anthony
Type
Journal Article
Abstract
Background: The antiviral oseltamivir is widely used for the treatment of critically ill patients with influenza. Evidence from randomised trials about its efficacy in the critically ill is lacking.
Methods: In an ongoing international, multifactorial, Bayesian adaptive platform, open-label randomised trial, we evaluated oseltamivir for 5 days, oseltamivir for 10 days, or no antiviral treatment in critically ill patients aged 12 years and older with confirmed influenza severe respiratory infection. The primary outcome was 90-day mortality. An odds ratio less than 1 indicates benefit from oseltamivir.
Findings: Between March 1, 2020 and March 13, 2026, 442 participants were randomised to receive 5 days of oseltamivir (n=162), 10 days of oseltamivir (n=156), or no antiviral (n=124). At a scheduled adaptive analysis, both oseltamivir durations met a predefined inferiority threshold (<0·2% probability of being the best treatment in the influenza antiviral domain), triggering cessation of recruitment. By day 90, 17 (13·7%) in the no antiviral group, 32 (19·8%) in the 5-day oseltamivir group, and 30 (19·4%) in the 10-day oseltamivir group had died. The median adjusted OR for 90-day mortality was 2·13 (95% CrI 1·03 to 4·52) for 5 days of oseltamivir and 2·17 (95% CrI 1·05 to 4·64) for 10 days of oseltamivir, favouring no antiviral. For the 5- and 10-day oseltamivir treatments, the posterior probabilities for harm, an adjusted OR >1, were 98·0% and 98·2%, respectively.
Interpretation: For critically ill patients with influenza, treatment with oseltamivir was ineffective. Unexpectedly, there was a signal of harm with oseltamivir use in this study.
Funding: Numerous
(ClinicalTrials.gov number, NCT02735707).
Methods: In an ongoing international, multifactorial, Bayesian adaptive platform, open-label randomised trial, we evaluated oseltamivir for 5 days, oseltamivir for 10 days, or no antiviral treatment in critically ill patients aged 12 years and older with confirmed influenza severe respiratory infection. The primary outcome was 90-day mortality. An odds ratio less than 1 indicates benefit from oseltamivir.
Findings: Between March 1, 2020 and March 13, 2026, 442 participants were randomised to receive 5 days of oseltamivir (n=162), 10 days of oseltamivir (n=156), or no antiviral (n=124). At a scheduled adaptive analysis, both oseltamivir durations met a predefined inferiority threshold (<0·2% probability of being the best treatment in the influenza antiviral domain), triggering cessation of recruitment. By day 90, 17 (13·7%) in the no antiviral group, 32 (19·8%) in the 5-day oseltamivir group, and 30 (19·4%) in the 10-day oseltamivir group had died. The median adjusted OR for 90-day mortality was 2·13 (95% CrI 1·03 to 4·52) for 5 days of oseltamivir and 2·17 (95% CrI 1·05 to 4·64) for 10 days of oseltamivir, favouring no antiviral. For the 5- and 10-day oseltamivir treatments, the posterior probabilities for harm, an adjusted OR >1, were 98·0% and 98·2%, respectively.
Interpretation: For critically ill patients with influenza, treatment with oseltamivir was ineffective. Unexpectedly, there was a signal of harm with oseltamivir use in this study.
Funding: Numerous
(ClinicalTrials.gov number, NCT02735707).
Date Acceptance
2026-11-04
Citation
The Lancet
ISSN
0140-6736
Publisher
Elsevier
Journal / Book Title
The Lancet
Copyright Statement
Copyright This paper is embargoed until publication. Once published the author’s accepted manuscript will be made available under a CC-BY License in accordance with Imperial’s Research Publications Open Access policy (www.imperial.ac.uk/oa-policy).
License URL
Publication Status
Accepted
